Avalanche Biotechnologies, Inc. (Nasdaq: AAVL) and Annapurna Therapeutics SAS, a privately held biopharmaceutical company, today announced that they have entered into a definitive agreement providing for the acquisition of all outstanding shares of Annapurna by Avalanche in exchange for approximately 17.6 million newly issued shares of Avalanche common stock.
